Lantheus enters two license/collaboration deals with POINT for up to $1.87B in milestones, $260M upfront

Lantheus Holdings, Inc.

Upfront cash: $250M for PNT-2002 (PSMA therapy) and $10M for PNT-2003 (SSTR therapy); combined potential milestones ~$1.87B.
PNT-2002 targets PSMA for metastatic castrate-resistant prostate cancer; POINT responsible for clinical development.
PNT-2003 targets SSTR-positive neuroendocrine tumors; Lantheus leads regulatory filings and commercialization post-approval.
Royalties: 20% PNT-2002 net sales after $500M cumulative gross profit; 15% PNT-2003 net sales.
Closing subject to HSR review; outside date June 30, 2023 (extendable by Lantheus to Aug 30, 2023).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Lantheus Holdings, Inc. entered into PNT-2002 License Agreement with POINT Biopharma Global Inc. valued at Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto (effective 2022-11-11).

Action: entry
Agreement: license
Counterparty: POINT Biopharma Global Inc.
Value: Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto
Effective: 2022-11-11

Exact text from the filing

On November 11, 2022, Lantheus Two, LLC (“Lantheus Two”), an indirect wholly owned subsidiary of Lantheus Holdings, Inc. (the “Company”), entered into a license and collaboration agreement (the “PNT-2002 License Agreement”) with an affiliate of POINT Biopharma Global Inc. (“POINT”), to co-develop and commercialize PNT-2002, a prostate-specific membrane antigen-targeted radiopharmaceutical therapy for the treatment of metastatic castrate-resistant prostate cancer.

View on SEC.gov

Browse all material agreements →

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-283698

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.